Stem cell patch for treating macular degeneration to enter phase 2b clinical trial

A stem cell patch developed by USC researchers for patients with macular degeneration will soon be tested in a phase 2b clinical trial.

This latest milestone in the patch's development was made possible by a combined $21 million in support from a state organization, a nonprofit foundation and the university. Last month, the California Institute for Regenerative Medicine (CIRM) awarded an estimated $12.4 million to the USC-supported startup Regenerative Patch Technologies (RPT) to test the safety and efficacy of the patch for treating advanced dry age-related macular degeneration, also known as "geographic atrophy."

The award from CIRM, a state institute that supports research to address unmet medical needs, is the latest round of funding for the startup. USC and The Marcus Foundation were also influential in the award.

Key supporters

To qualify for CIRM funds, applicants must have a substantial amount of co-funding. USC Research and Innovation provided a $2 million promissory note to partially fulfill the co-funding requirement. The Marcus Foundation in Atlanta also played a critical role, providing USC researcher Mark Humayun and the university with more than $7 million in a peer-reviewed grant for this novel, transformational stem cell research program at USC that is aimed at curing blindness.

I want to thank USC President Carol L. Folt for supporting this important research, as well as USC Research and Innovation for all the work they did to make this possible. I would also like to thank The Marcus Foundation for their generous support after a thorough review process."

Humayun, director of the USC Ginsburg Institute for Biomedical Therapeutics and co-director of the USC Gayle and Edward Roski Eye Institute

USC Research and Innovation's award came from a first-of-its-kind, dedicated research program that supports USC faculty partnerships with small businesses to plan competitive funding applications.

"We are thrilled to support this critically important medical innovation by fostering the university's ongoing technology transfer and commercialization efforts through faculty partnerships with small businesses," said Ishwar K. Puri, senior vice president for USC Research and Innovation.

A patch with promise

Geographic atrophy affects more than 1 million Americans ages 40 and older, according to data from the Centers for Disease Control and Prevention. Currently, there is no therapy to improve vision in patients who have the condition.

Research on the patch so far has indicated positive results. It appears to restore the structure and function of the retina to improve vision. The phase 2b clinical trial will involve evaluating the efficacy of the implant in 24 patients who have suffered vision loss from geographic atrophy.

The disease affects a vital group of cells: retinal pigment epithelium (RPE) cells. When healthy, these cells enable photoreceptor cells of the retina to detect light. With geographic atrophy, RPE cells degenerate over time. This can lead to photoreceptor loss, impaired vision and, for many, blindness, forcing some patients to lose their independence.

"CIRM is proud to continue to fund this groundbreaking stem cell therapy that has the potential to improve outcomes for the millions of people suffering from geographic atrophy," Maria T. Millan, president and chief executive officer of CIRM, said in an announcement of the award. "This investment is follow-on funding to CIRM's previous support to develop this therapy. It reflects our commitment to advancing cutting-edge science and underscores our dedication to addressing the unmet medical needs of those affected by degenerative diseases."

The researchers realizing the vision

Humayun and his fellow co-founders of Regenerative Patch Technologies -; Dennis Clegg, professor in the department of molecular, cellular and developmental biology at the University of California, Santa Barbara; and the late David Hinton, professor of ophthalmology and pathology at USC -; had developed the core technology for the stem cell-based subretinal implant.

The implant, named the "California Project to Cure Blindness-Retinal Pigment Epithelium 1" or CPCB-RPE1, is licensed by the USC Stevens Center for Innovation exclusively to Regenerative Patch Technologies.

The phase 2b clinical trial at USC will be led by Sun Young Lee and Rodrigo Antonio Brant Fernandes, both MDs and faculty members at the USC Roski Eye Institute.

Previously, the Alfred E. Mann Institute at USC had provided support for the initial development of the implantable patch as an incubator for new USC-related companies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Low-dose atropine eyedrops not effective in slowing myopia progression in children